| 16.77 Data as of Jun 06 |  +0.34 / +2.07%Today’s Change | 10.85 Today|||52-Week Range 18.83 | +31.53% Year-to-Date |
| Previous close | 16.43 |
| Today’s open | 16.43 |
| Day’s range | -- - -- |
| Volume | 494,242 |
| Average volume (3 months) | 706,345 |
| Market cap | $1.4B |
| Dividend yield | -- |
| Earnings growth (last year) | -11.76% |
| Earnings growth (this year) | +3.24% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -15.27% |
| P/E ratio | NM |
| Price/Sales | 78.61 |
| Price/Book | 15.23 |
| Today’s change | Today’s % change | |
|---|---|---|
| GEVASynageva Biopharma C... | +0.69 | +1.74% |
| ITMNInterMune Inc | +0.19 | +1.99% |
| SZYMSolazyme Inc | -0.46 | -3.95% |
| HALOHalozyme Therapeutic... | +0.09 | +1.44% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.30 |
| Annual revenue (last year) | $16.4M |
| Annual profit (last year) | -$73.3M |
| Net profit margin | -448.24% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Daniel M. Junius |
Chief Financial Officer, Treasurer & Executive VP Gregory D. Perry |
Corporate headquarters Waltham, Massachusetts |
.
